Key biomarkers that can provide clues to the presence of a variety of diseases are abundant in the interstitial fluid that surrounds cells, which serves as a conduit between blood and tissue. A new type of nano-needle developed by Sandia National Laboratories and the University of New Mexico can provide easier and less invasive diagnostics than previous methods by accessing interstitial fluid in the skin.
Quest Diagnostics posted $1.84 billion in revenues during the fourth quarter of 2018, down 1.4% compared to the same year-ago period. The company expects its full-year 2019 revenues to reach between $7.6 billion and $7.75 billion.
A financing round led by Olive Tree Ventures brought in $6 million for Emedgene, an Israel-based firm offering genetic test interpretation solutions. The money will be used to help expand genomics-based care with artificial intelligence, as well as the company's US sales operations.
The Democratic Republic of Congo's health ministry said the city of Beni has completed 21 days without reports of new cases of Ebola virus infection, though reintroduction remains a risk. Four new cases have been reported in Butembo and Katwa.
BioBridge Global subsidiary GenCure plans to launch a biomanufacturing laboratory at an innovation center under development in San Antonio. GenCure provides researchers with adult stem cells derived from cord blood and bone marrow cells.
Investigators found that Terumo BCT's Spectra Optia, a cell-separation device, was associated with a 16% reduced usage of red blood cell packs by sickle cell disease patients compared with standard transfusions. The study was reported in the journal Transfusion.
The Broad Institute of MIT and Harvard is unveiling the Gerstner Center for Cancer Diagnostics at the Broad Institute, through which researchers will develop a biopsy procedure to detect and monitor cancer using a blood draw.
The CMS' update to Protecting Access to Medicare Act regulations, which expanded the definition of "applicable laboratory" for private payer data reporting to include laboratories that use the 14x type bill to submit Medicare claims, is designed to paint a more diverse picture of laboratory test payments. However, it's unclear whether this will lead to a significant rate increase in the CMS' next calculation of weighted median rates, as the 14x bill is used by just 12% of hospital laboratories.
A $75 million donation will help NYU Langone Health's Laura and Isaac Perlmutter Cancer Center start a Center for Blood Cancers. Officials say the center aims to increase patient recruitment for trials, promote research and seek to identify markers for different blood malignancies.
Preliminary data from a late-stage clinical trial showed that patients with hematologic malignancies who received umbilical cord blood grafts expanded ex vivo with nicotinamide, or NiCord, had median post-transplant neutrophil recovery time decreased by almost 50% compared with patients who received standard UCB transplantation, and incidence of graft-versus-host disease was also lower in patients receiving NiCord cells. "This study suggests that NiCord obviates the need for a second UCB graft. NiCord paves the way for use of smaller, better-matched units for adult patients that otherwise could not be used because of excessive risk of graft failure," the study team wrote in the Journal of Clinical Oncology.
- Page 1